Skip to content

How does MRD guide treatment decisions in ALL?
Targeted immune CTCL therapy set for US launch in Q4 2025
Pathways & Perspectives with Gabriela Hobbs, MD
FDA approves revumenib in relapsed or refractory NMP1-mutated AML
FDA approves blenrep combo in relapsed or refractory MM

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Kami Maddocks, MD

Cellular Therapy

Kami Maddocks, MD

Leukemia

Kami Maddocks, MD

Lymphoma

Kami Maddocks, MD

Multiple Myeloma

Kami Maddocks, MD

Myelodysplastic Syndromes

Kami Maddocks, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

October 28, 2025

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Kami Maddocks, MD

Kami Maddocks, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
302 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

Leukemia News, SOHO 2025, News, Video Interviews

How does MRD guide treatment decisions in ALL?

October 28, 2025

handshake

Lymphoma, T-Cell Lymphoma, News

Targeted immune CTCL therapy set for US launch in

October 28, 2025

Leukemia, Acute Lymphoblastic Leukemia, Myeloproliferative Neoplasms, News

Pathways & Perspectives with Gabriela Hobbs, MD

October 27, 2025

Leukemia, Acute Myeloid Leukemia

FDA approves revumenib in relapsed or refractory NMP1-mutated AML

October 24, 2025

FDA approved

Multiple Myeloma

FDA approves blenrep combo in relapsed or refractory MM

October 23, 2025

FDA editorial

Myelodysplastic Syndromes, News

FDA grants orphan drug designation to MDS investigational therapy

October 23, 2025

Top Categories

Cellular Therapy

13

Leukemia

61

Lymphoma

58

Multiple Myeloma

48

Myelodysplastic Syndromes

23

Myeloproliferative Neoplasms

12

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Kami Maddocks, MD

Cellular Therapy

Kami Maddocks, MD

Leukemia

Kami Maddocks, MD

Lymphoma

Kami Maddocks, MD

Multiple Myeloma

Kami Maddocks, MD

Myelodysplastic Syndromes

Kami Maddocks, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

How does MRD guide treatment decisions in ALL?

handshake

Targeted immune CTCL therapy set for US launch in Q4 2025

Pathways & Perspectives with Gabriela Hobbs, MD

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.